Viking Therapeutics, Inc. - COMMON STOCK (VKTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2015 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
VKTX on Nasdaq
Shares outstanding
113,177,462
Price per share
$35.18
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
71,246,268
Total reported value
$1,872,344,324
% of total 13F portfolios
0%
Share change
-4,913,247
Value change
-$130,051,179
Number of holders
363
Price from insider filings
$35.18
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 5.1% -40% $151,689,488 -$105,010,859 5,772,051 -41% FMR LLC 30 Sep 2025
BlackRock, Inc. 4.5% -16% $111,800,174 -$18,689,931 5,031,511 -14% BlackRock, Inc. 31 Mar 2025

As of 30 Sep 2025, 363 institutional investors reported holding 71,246,268 shares of Viking Therapeutics, Inc. - COMMON STOCK (VKTX). This represents 63% of the company’s total 113,177,462 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) together control 47% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.8% 9,999,107 -1.6% 0% $262,776,531
FMR LLC 5.1% 5,790,051 -41% 0.01% $152,162,529
BlackRock, Inc. 4.9% 5,596,166 +2.9% 0% $147,067,246
STATE STREET CORP 4% 4,513,832 +20% 0% $118,623,505
MORGAN STANLEY 3.3% 3,729,117 +15% 0.01% $98,001,218
JPMORGAN CHASE & CO 2.3% 2,577,087 -2.3% 0% $67,725,865
SUSQUEHANNA INTERNATIONAL GROUP, LLP 1.9% 2,099,564 +1.6% 0.08% $55,176,542
AMERIPRISE FINANCIAL INC 1.8% 2,092,840 +42% 0.01% $54,999,836
TWO SIGMA INVESTMENTS, LP 1.8% 2,085,487 +59% 0.08% $54,806,598
CITADEL ADVISORS LLC 1.7% 1,898,342 +117% 0.04% $49,888,428
GEODE CAPITAL MANAGEMENT, LLC 1.4% 1,608,606 -16% 0% $42,284,245
TWO SIGMA ADVISERS, LP 1.4% 1,555,128 +42% 0.08% $40,868,764
UBS Group AG 1.2% 1,342,308 +41% 0.01% $35,275,855
Pictet Asset Management Holding SA 1.1% 1,196,305 -38% 0.03% $31,438,895
RAYMOND JAMES FINANCIAL INC 0.84% 954,272 +16% 0.01% $25,078,269
TANG CAPITAL MANAGEMENT LLC 0.77% 870,000 +135% 0.88% $22,863,600
JANE STREET GROUP, LLC 0.7% 793,806 +8.4% 0.02% $20,861,222
BRAIDWELL LP 0.67% 759,455 -47% 0.59% $19,958,477
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.62% 697,708 -4.1% 0% $18,335,766
ROYAL BANK OF CANADA 0.57% 648,295 +6% 0% $17,037,000
BANK OF AMERICA CORP /DE/ 0.51% 578,268 +10% 0% $15,196,884
NORTHERN TRUST CORP 0.49% 557,269 +2.6% 0% $14,645,029
Connor, Clark & Lunn Investment Management Ltd. 0.48% 544,201 +22% 0.05% $14,301,602
PRINCIPAL FINANCIAL GROUP INC 0.45% 514,002 -9% 0.01% $13,507,972
BlackBarn Capital Partners LP 0.44% 500,000 +43% 4.3% $13,140,000

Institutional Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 630,667 $21,602,375 +$3,002,550 $35.18 52
2025 Q3 71,246,268 $1,872,344,324 -$130,051,179 $26.28 363
2025 Q2 76,160,666 $2,018,412,050 +$15,581,287 $26.50 386
2025 Q1 76,178,049 $1,840,349,432 -$233,469,503 $24.15 365
2024 Q4 81,954,269 $3,297,744,791 -$89,660,583 $40.24 404
2024 Q3 81,646,248 $5,169,001,224 +$153,200,364 $63.31 427
2024 Q2 80,339,291 $4,258,766,049 -$165,248,173 $53.01 389
2024 Q1 79,927,953 $6,553,241,666 +$414,126,060 $82.00 376
2023 Q4 258,776 $4,868,621 -$812,602 $18.61 4
2023 Q3 76,820,073 $850,392,405 +$8,132,328 $11.07 175
2023 Q2 74,182,176 $1,202,358,398 +$120,052,219 $16.21 190
2023 Q1 66,463,837 $1,106,888,845 +$546,599,860 $16.65 182
2022 Q4 34,003,932 $319,613,212 +$76,441,457 $9.40 126
2022 Q3 26,398,821 $71,804,762 +$425,801 $2.72 92
2022 Q2 25,565,729 $73,307,891 -$13,642,948 $2.89 91
2022 Q1 30,477,535 $91,499,398 -$17,066,465 $3.00 126
2021 Q4 35,948,569 $165,314,159 -$7,731,542 $4.60 129
2021 Q3 37,084,508 $233,393,655 +$703,827 $6.28 125
2021 Q2 37,713,543 $225,937,479 -$18,886,312 $5.99 131
2021 Q1 40,902,589 $258,667,860 +$21,348,949 $6.32 138
2020 Q4 37,667,435 $212,223,882 -$11,008,964 $5.63 133
2020 Q3 39,483,804 $229,802,043 -$3,957,019 $5.82 136
2020 Q2 39,948,272 $287,973,852 +$7,624,415 $7.21 127
2020 Q1 35,593,463 $166,545,493 -$7,943,732 $4.68 123
2019 Q4 39,252,276 $314,813,059 -$6,186,403 $8.02 128
2019 Q3 40,484,433 $278,533,135 -$33,556,872 $6.88 136
2019 Q2 45,064,927 $374,042,879 -$7,413,079 $8.30 148
2019 Q1 45,714,566 $454,289,676 -$5,084,578 $9.94 157
2018 Q4 46,770,344 $357,761,721 -$8,642,066 $7.65 155
2018 Q3 43,213,947 $749,654,331 +$278,746,257 $17.42 146
2018 Q2 31,473,265 $297,258,644 +$125,463,389 $9.49 114
2018 Q1 20,905,622 $91,354,000 +$50,563,886 $4.37 62
2017 Q4 9,329,591 $37,876,000 +$30,074,055 $4.06 32
2017 Q3 2,021,286 $3,851,000 +$1,491,311 $1.91 16
2017 Q2 1,566,472 $1,690,000 +$856,279 $1.08 9
2017 Q1 769,601 $1,124,000 +$226,912 $1.46 10
2016 Q4 634,780 $756,000 -$869,280 $1.19 10
2016 Q3 1,209,377 $1,700,000 +$496,033 $1.41 12
2016 Q2 859,444 $1,082,000 +$1,025,602 $1.26 11
2016 Q1 44,443 $65,000 -$25,997 $1.53 6
2015 Q4 41,278 $140,000 -$14,614 $3.36 5
2015 Q3 43,175 $252,000 -$77,596 $5.83 6
2015 Q2 54,005 $384,000 +$383,999 $7.10 5